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Patterns of Fatigue in Patients Receiving Chemotherapy
crF fluctuates over time and peaks in the days immediately after iv chemotherapy administration. richardson, ream, and Wilson-Barnett (1998) revealed that patients with cancer who were treated by conventional three-or four-week regimens reported high levels of fatigue for the first four to five days after chemotherapy. Fatigue decreased steadily in subsequent days until around day 15, when a temporary Key Points . . . ➤ cancer-related fatigue (crF) peaks in the days immediately after iv chemotherapy and declines gradually over time.
➤ Exercise has an impact on levels of crF.
➤ Fatigue patterns vary depending on the type of chemotherapy regimen patients receive. Methods: The data were collected as part of a randomized clinical trial to test the effectiveness of a systematic exercise intervention on fatigue. Participants were classified as exercisers or nonexercisers according to the Surgeon General's Guideline for Physical Activity criteria. Average and worst fatigue levels in the prior 24 hours were measured on a 0-10 numeric rating scale at bedtime for 21 consecutive days beginning on the day of chemotherapy.
Main Research Variables: Average and worst levels of fatigue, exercise status, and chemotherapy regimens.
Findings: Average and worst levels of fatigue peaked immediately after chemotherapy and declined gradually over time. The decreases were significant (p < 0.001) but not different between exercisers and nonexercisers. Fatigue of doxorubicin and cyclophosphamide (AC) regimens was more severe, especially for the first three days after chemotherapy, and more prolonged than those of non-AC regimens.
Conclusions: The patterns of change in fatigue were similar between exercisers and nonexercisers, but nonexercisers consistantly reported higher fatigue levels during the third cycle of chemotherapy. The patterns of fatigue differed by chemotherapy regimens.
Implications for Nursing: The information of fatigue trajectories is crucial in preparing patients for chemotherapy and determining the timing of interventions and measurement of outcomes.
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